A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole

Table 4 Association of clinical, pathological and genotypic parameters with progression free survival (PFS).

Parameters	n	Events	%PFS	p
Tumor size
T2	76	12	62.6	0.089
T3-T4	19	6	59.3
Lymph node involvement
N0	76	10	57.31	0.0011
N1-N2	19	8	44.7
Stage
IIa	65	8	58.2	0.0232
IIb	20	6	65.1
IIIa-IIIb	10	4	42.3
RR4M
Responders	35	1	96.7	0.0033
Non-responders	60	17	45.6
rs10046
GG	18	3	80.0	0.967
AG/AA	80	15	81.3
rs4646
CC	57	7	85.7	0.0686
AC/AA	38	11	50.9

ISSN: 1471-2407